Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer
暂无分享,去创建一个
R. Orecchia | S. Gandini | P. Maisonneuve | C. Garibaldi | R. Cambria | S. Volpe | G. Marvaso | A. Starzyńska | B. Jereczek-Fossa | D. Ciardo | F. Cattani | D. Zerini | C. Fodor | A. Vavassori | M. Ferro | G. Riva | F. Nolè | M. A. Zerella | G. Fanetti | A. Surgo | A. Maucieri | G. Musi | S. Arculeo | S. Parisi | O. Alessandro | O. Cobelli | Franco Nolè | Patrick Maisonneuve | R. Orecchia | Sara Gandini | Giuseppe Fanetti | O. D. Cobelli | M. Ferro
[1] P. Dasgupta,et al. National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer. , 2017, International journal of radiation oncology, biology, physics.
[2] G. Sanguineti,et al. Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Kuban,et al. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial , 2016, American journal of clinical oncology.
[4] B. Heijmen,et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[5] S. Arcangeli,et al. Hypofractionated radiotherapy for organ-confined prostate cancer: is less more? , 2016, Nature Reviews Urology.
[6] J. Lebesque,et al. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. , 2016, International journal of radiation oncology, biology, physics.
[7] Qiong-wen Zhang,et al. The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures , 2016, PloS one.
[8] E. Horwitz,et al. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. , 2015, International journal of radiation oncology, biology, physics.
[9] A. D'Amico,et al. A systematic review of hypofractionation for primary management of prostate cancer. , 2015, European urology.
[10] D. Dearnaley,et al. 8LBA 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group , 2015 .
[11] R. Orecchia,et al. Image-Guided Radiotherapy for Prostate Cancer using 3 Different Techniques: Localization Data of 186 Patients , 2015, Tumori.
[12] Marnix G Witte,et al. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. , 2015, International journal of radiation oncology, biology, physics.
[13] R. Orecchia,et al. Planning study to compare dynamic and rapid arc techniques for postprostatectomy radiotherapy of prostate cancer , 2014, Strahlentherapie und Onkologie.
[14] P. Jean-Pierre,et al. Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With Conventional versus Hypofractionated Intensity Mediated Radiotherapy: A Phase III Hypofractionation Trial , 2011 .
[15] R. Orecchia,et al. Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation. , 2011, Urologic oncology.
[16] Anthony Fyles,et al. Long-term results of hypofractionated radiation therapy for breast cancer. , 2010, The New England journal of medicine.
[17] M. Ritter. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. , 2008, Seminars in radiation oncology.
[18] Cristina Garibaldi,et al. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients. , 2008, International journal of radiation oncology, biology, physics.
[19] Alexandra L Hanlon,et al. What dose of external-beam radiation is high enough for prostate cancer? , 2007, International journal of radiation oncology, biology, physics.
[20] R. Orecchia,et al. Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: comparison of two treatment techniques (six coplanar fields and two dynamic arcs). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[21] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[22] C. Ma,et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. , 2006, International journal of radiation oncology, biology, physics.
[23] C. Reddy,et al. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. , 2003, International journal of radiation oncology, biology, physics.
[24] Roberto Orecchia,et al. Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[25] Patrick A. Kupelian,et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. , 2007, International journal of radiation oncology, biology, physics.
[26] F. Vicini,et al. Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better? , 2001, International journal of radiation oncology, biology, physics.
[27] S. L. Morgan-Fletcher. Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50), ICRU Report 62. ICRU, pp. ix+52, 1999 (ICRU Bethesda, MD) $65.00 ISBN 0-913394-61-0 , 2001 .
[28] W. De Gersem,et al. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. , 2000, International journal of radiation oncology, biology, physics.
[29] C C Ling,et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[30] T. Pajak,et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.
[31] R. Stoyanova,et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[33] N. Dubrawsky. Cancer statistics , 2022 .